Table 2.
Univariate analysis using log-rank test of potential pathological prognostic factors in preoperative CCRT patients
| No local recurrence, 56 n (%) | Local recurrence, 14 n (%) |
12-month disease-free survival (%) | 36-month disease-free survival (%) |
60-month disease-free survival (%) |
P-value | |
|---|---|---|---|---|---|---|
| Age (year) mean, (± SD), (min, max) |
60.75 (±11.88) (32, 80) |
61.21 (±13.60) (31, 82) |
- | - | - | 0.8992* |
| Sex | ||||||
| Female | 23 (41.07) | 2 (14.29) | - | - | - | 0.061** |
| Male | 33 (58.93) | 12 (85.71) | - | - | - | |
| Location | 0.8423 | |||||
| Upper rectum | 12 (21.43) | 3 (21.43) | 100 | 71.43 | NA | |
| Middle rectum | 12 (21.43) | 3 (21.43) | 90.91 | 38.96 | NA | |
| Lower rectum | 31 (55.36) | 8 (57.14) | 85.93 | 72.54 | 72.54 | |
| Anal canal | 1 (1.78) | 0 (0.00) | 100 | 100 | NA | |
| Histologic type | 0.8234 | |||||
| No viable tumor | 10 (17.86) | 2 (14.29) | 90.91 | 68.18 | NA | |
| Adenocarcinoma | 46 (82.14) | 12 (85.71) | 89.83 | 69.95 | 69.95 | |
| Differentiation | 0.7421 | |||||
| Well differentiated | 36 (64.89) | 9 (64.29) | 88.01 | 72.12 | 72.12 | |
| Moderately differentiated | 17 (30.36) | 5 (35.71) | 92.31 | 58.74 | NA | |
| Poorly differentiated | 3 (5.36) | 0 (0.00) | 100 | 100 | NA | |
| Tumor response grade: Modified Ryan Scheme | 0.7306 | |||||
| Grade 0 | 10 (17.86) | 2 (14.29) | 90.91 | 68.18 | NA | |
| Grade 1 | 10 (17.86) | 1 (7.14) | 88.89 | 88.89 | NA | |
| Grade 2 | 26 (46.43) | 7 (50.00) | 92.35 | 71.26 | 71.26 | |
| Grade 3 | 10 (17.86) | 4 (28.57) | 85.12 | 60.8 | NA | |
| ypT stage | 0.0093 | |||||
| T0–T2 | 31 (55.36) | 3 (21.43) | 96.55 | 87.77 | 87.77 | |
| T3–T4 | 25 (44.46) | 11 (78.57) | 83.58 | 54.26 | NA | |
| Lymphatic space invasion | 0.0033 | |||||
| Negative | 40 (71.43) | 3 (21.43) | 94.44 | 87.69 | NA | |
| Positive | 16 (28.57) | 11 (78.57) | 83.01 | 46.77 | 46.77 | |
| Venous invasion | 0.0345 | |||||
| Negative | 45 (80.36) | 6 (42.86) | 93.25 | 80.4 | 80.4 | |
| Positive | 11 (19.64) | 8 (57.14) | 81.37 | 47.55 | NA | |
| Perineural invasion | 0.1368 | |||||
| Negative | 43 (76.79) | 8 (57.14) | 90.23 | 77.53 | 77.53 | |
| Positive | 13 (23.21) | 6 (42.86) | 88.89 | 53.28 | NA | |
| N stage | 0.2075 | |||||
| 0 | 40 (71.43) | 7 (50.00) | 95.45 | 73.48 | 73.48 | |
| 1 | 13 (23.21) | 5 (35.71) | 72.73 | 63.64 | NA | |
| 2 | 3 (5.36) | 2 (14.29) | 80 | 60 | NA | |
| Circumferential margin | 0.0003 | |||||
| Negative | 55 (98.21) | 10 (71.43) | 90.91 | 79.01 | 79.01 | |
| Positive | 1 (1.79) | 4 (28.57) | 80 | 0 | 0 | |
| Distal margin | 0.5445 | |||||
| Negative | 55 (98.21) | 14 (100.00) | 89.72 | 68.8 | 68.8 | |
| Positive | 1 (1.79) | 0 (0.00) | 100 | 100 | NA | |
| Proximal margin | 0.2709 | |||||
| Negative | 56 (100.00) | 13 (92.86) | 89.72 | 73.39 | 73.39 | |
| Positive | 0 (0.00) | 1 (7.14) | 100 | 0 | 0 | |
| ypTNM staging | 0.0109 | |||||
| Stage 0-2 | 31 (55.36) | 3 (21.43) | 96.77 | 84.04 | 84.04 | |
| Stage 3-4 | 25 (44.64) | 11 (78.57) | 82.69 | 54.77 | NA | |
*, Student t-test; **, Chi-square test